STOCK TITAN

Eyenovia Inc - EYEN STOCK NEWS

Welcome to our dedicated news page for Eyenovia (Ticker: EYEN), a resource for investors and traders seeking the latest updates and insights on Eyenovia.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Eyenovia's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Eyenovia's position in the market.

Rhea-AI Summary
Eyenovia, Inc. (NASDAQ: EYEN) will release its financial results for the third quarter ended September 30, 2023, on November 13, 2023. The company will host an investor conference call and webcast at 4:30 p.m. EDT to review the financial and operating results. Eyenovia is an ophthalmic technology company commercializing Mydcombi™ for mydriasis and preparing for regulatory approval of APP13007 for relief of pain and inflammation post ocular surgery. They are also incorporating their advanced Optejet® device with late-stage product candidates for presbyopia and pediatric progressive myopia as well as out-licensing for additional indications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.74%
Tags
conferences earnings
-
Rhea-AI Summary
Eyenovia, Inc. has received FDA approval for its Supplemental New Drug Application (sNDA), adding Coastline International as a contract manufacturer. Coastline will manufacture cartridge subassemblies for Mydcombi, an FDA-approved tropicamide and phenylephrine hydrochloride fixed combination for mydriasis. Eyenovia anticipates initiating commercial production soon and aims to have the product available to ship in January 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.13%
Tags
-
Rhea-AI Summary
Eyenovia, Inc. is sponsoring a course at the International Joint Commission on Allied Health Personnel in Ophthalmology (IJCAHPO) 51st Annual Continuing Education (ACE) program. The course will provide ophthalmic technicians with training on the use of Mydcombi™ for mydriasis and background on the Optejet dispensing technology. Eyenovia plans to launch Mydcombi commercially in early 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.48%
Tags
none
Rhea-AI Summary
Eyenovia to present on microbial integrity of Optejet device at American Academy of Optometry’s Annual Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.56%
Tags
conferences
-
Rhea-AI Summary
Eyenovia CEO to participate in panel discussion at Cantor Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.81%
Tags
conferences
-
Rhea-AI Summary
Eyenovia, Inc. to present at H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.07%
Tags
conferences
Rhea-AI Summary
Eyenovia announces Securities Purchase Agreement, offering of common stock and warrants
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.69%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.44%
Tags
-
Rhea-AI Summary
Formosa Pharmaceuticals (6838.TWO) has entered into a licensing agreement with Eyenovia, Inc. (NASDAQ: EYEN) for the exclusive U.S. rights to commercialize APP13007, a treatment for inflammation and pain following ocular surgery. The deal is worth $86 million and includes upfront payment, development and sales milestones. APP13007 is currently under FDA review and has a PDUFA date of March 4, 2024. If approved, it will enter a $1.3 billion market for topical ophthalmic steroids and steroid combinations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.44%
Tags
none
Rhea-AI Summary
Eyenovia, Inc. announced FDA approval and first commercial sale of Mydcombi™, a fixed dose combination of tropicamide and phenylephrine for mydriasis. The company also provided updates on its Phase 3 Apersure™ presbyopia candidate and manufacturing facilities. Second quarter financial results showed a net loss of $(6.2) million. The company will host a conference call and webcast on August 10.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.46%
Tags
Eyenovia Inc

Nasdaq:EYEN

EYEN Rankings

EYEN Stock Data

25.11M
36.54M
16.2%
22.44%
11.02%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States
New York

About EYEN

eyenovia, inc. (nasdaq: eyen) is a specialty biopharmaceutical company building a portfolio of next generation topical eye treatments based on its proprietary delivery and formulation platform for microdosing. eyenovia’s pipeline is currently focused on the late-stage development of microdosed medications for myopia progression, presbyopia, mydriasis and other eye diseases.